drugset
Drugs / ABBV-706
last change Jun 2026 re-read 2 minutes ago

ABBV-706

Other / unclassified targets SEZ6

Developed for
small cell lung carcinoma · cancer
Investigated by
AbbVie

Trials 3 · a red edge is where a trial was stopped

today NCT07365241 · Ph 3 NCT07155174 · Ph 2 NCT05599984 · Ph 1
20232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05599984 Dec 2022 → Nov 2027 expected cancer AbbVie Active not recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT07155174 Nov 2025 → Apr 2029 expected small cell lung carcinoma AbbVie Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT07365241 Apr 2026 → Sep 2030 expected small cell lung carcinoma AbbVie Not yet recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT07310277 Background — small cell lung carcinoma AbbVie Available No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as ABBV-706 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07365241 ↗
3

NCT05599984 ↗

NCT07155174 ↗

NCT07310277 ↗
Modality Other / unclassified “ABBV-706, an antibody-drug conjugate with a SEZ6-directed antibody linked to topoisomerase-1 inhibitor (Top1i)” PMID 42225988 ↗ Jun 2026
Route Intravenous “was administered intravenously every 3 weeks (Q3W)” PMID 42225988 ↗ Jun 2026
Target SEZ6 “ABBV-706, an antibody-drug conjugate with a SEZ6-directed antibody linked to topoisomerase-1 inhibitor (Top1i)” PMID 42225988 ↗ Jun 2026